Multiple myeloma(MM) cells express CD38 in high levels, whereas the expression levels of CD38 are lower in normal myeloid and lymphoid cells as well as some non-hematopoietic tissues, driving the development of anti-CD38 monoclonal antibodies (mAbs) in the treatment of MM. The gene discussed is CD38; the disease is Miyoshi myopathy.